Abstract
Patients with smouldering or asymptomatic multiple
myeloma (SMM) are not treated until symptomatic disease
develops. SMM is characterised by a serum monoclonal
protein component of 3 g/dL or plasma cell infiltration
into bone marrow of 10% or more.
| Original language | English |
|---|---|
| Pages (from-to) | 240-241 |
| Number of pages | 2 |
| Journal | Journal of Pharmacy Practice and Research |
| Volume | 43 |
| Issue number | 3 |
| Publication status | Published - 2013 |